Literature DB >> 19442172

The role of the gut microbiota in energy metabolism and metabolic disease.

Patrice D Cani1, Nathalie M Delzenne.   

Abstract

Obesity is now classically characterized by a cluster of several metabolic disorders, and by a low grade inflammation. The evidence that the gut microbiota composition can be different between healthy and or obese and type 2 diabetic patients has led to the study of this environmental factor as a key link between the pathophysiology of metabolic diseases and the gut microbiota. Several mechanisms are proposed linking events occurring in the colon and the regulation of energy metabolism, such as i.e. the energy harvest from the diet, the synthesis of gut peptides involved in energy homeostasis (GLP-1, PYY...), and the regulation of fat storage. Moreover, the development of obesity and metabolic disorders following a high-fat diet may be associated to the innate immune system. Indeed, high-fat diet feeding triggers the development of obesity, inflammation, insulin resistance, type 2 diabetes and atherosclerosis by mechanisms dependent of the LPS and/or the fatty acids activation of the CD14/TLR4 receptor complex. Importantly, fat feeding is also associated with the development of metabolic endotoxemia in human subjects and participates in the low-grade inflammation, a mechanism associated with the development of atherogenic markers. Finally, data obtained in experimental models and human subjects are in favour of the fact that changing the gut microbiota (with prebiotics and/or probiotics) may participate in the control of the development of metabolic diseases associated with obesity. Thus, it would be useful to find specific strategies for modifying gut microbiota to impact on the occurrence of metabolic diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19442172     DOI: 10.2174/138161209788168164

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  259 in total

Review 1.  Impact of liver diseases on the development of type 2 diabetes mellitus.

Authors:  Po-Shiuan Hsieh; Yen-Ju Hsieh
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

2.  High-level dietary fibre up-regulates colonic fermentation and relative abundance of saccharolytic bacteria within the human faecal microbiota in vitro.

Authors:  Qing Shen; Lu Zhao; Kieran M Tuohy
Journal:  Eur J Nutr       Date:  2011-09-28       Impact factor: 5.614

Review 3.  Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases?

Authors:  John Heineman; Sara Bubenik; Stephen McClave; Robert Martindale
Journal:  Curr Gastroenterol Rep       Date:  2012-08

4.  Oral supplementation with Lactobacillus delbrueckii subsp. bulgaricus 8481 enhances systemic immunity in elderly subjects.

Authors:  Marco Antonio Moro-García; Rebeca Alonso-Arias; Maria Baltadjieva; Carlos Fernández Benítez; Manuel Amadeo Fernández Barrial; Enrique Díaz Ruisánchez; Ricardo Alonso Santos; Magdalena Alvarez Sánchez; Juan Saavedra Miján; Carlos López-Larrea
Journal:  Age (Dordr)       Date:  2012-05-30

Review 5.  Satiety Innovations: Food Products to Assist Consumers with Weight Loss, Evidence on the Role of Satiety in Healthy Eating: Overview and In Vitro Approximation.

Authors:  Rubén López-Nicolás; Massimo Marzorati; Lia Scarabottolo; Jason C G Halford; Alexandra M Johnstone; Carmen Frontela-Saseta; Angel M Sanmartín; Gaspar Ros-Berruezo; Joanne A Harrold
Journal:  Curr Obes Rep       Date:  2016-03

6.  Effects of high performance inulin supplementation on glycemic status and lipid profile in women with type 2 diabetes: a randomized, placebo-controlled clinical trial.

Authors:  Parvin Dehghan; Bahram Pourghassem Gargari; Mohammad Asgharijafarabadi
Journal:  Health Promot Perspect       Date:  2013-06-30

7.  Changes in weight loss and lipid profiles after a dietary purification program: a prospective case series.

Authors:  Erica Callahan
Journal:  J Chiropr Med       Date:  2013-03

Review 8.  Insulin resistance in obesity: an overview of fundamental alterations.

Authors:  Rocco Barazzoni; Gianluca Gortan Cappellari; Maurizio Ragni; Enzo Nisoli
Journal:  Eat Weight Disord       Date:  2018-02-03       Impact factor: 4.652

Review 9.  Microbiota and metabolic diseases.

Authors:  Alessia Pascale; Nicoletta Marchesi; Cristina Marelli; Adriana Coppola; Livio Luzi; Stefano Govoni; Andrea Giustina; Carmine Gazzaruso
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

Review 10.  Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.

Authors:  Zora Djuric
Journal:  Transl Res       Date:  2016-07-28       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.